{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T02:33:27Z","timestamp":1768617207156,"version":"3.49.0"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1080\/10673220590923164","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T04:51:38Z","timestamp":1126759898000},"page":"28-42","source":"Crossref","is-referenced-by-count":24,"title":["Toward Convergence in the Medication Treatment of Bipolar Disorder and Schizophrenia"],"prefix":"10.1097","volume":"13","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/archpsyc.1978.01770310017001","article-title":"Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of schizophrenic symptoms in the light of current research.","volume":"35","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00325481.1989.11700634","article-title":"Differential diagnosis of psychosis, a brief guide for the primary care physician.","volume":"85","author":"Citrome","year":"1989","journal-title":"Postgrad Med"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/14737175.2.1.69","article-title":"Atypical antipsychoticsevolutionary or incremental advance.","volume":"2","author":"Citrome","year":"2002","journal-title":"Exp Re Neurother"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1176\/appi.ps.53.10.1212","article-title":"Datapointsmood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994-2001.","volume":"53","author":"Citrome","year":"2002","journal-title":"Psychiatr Serv"},{"issue":"suppl 11","key":"R6-3-20210129","first-page":"1","article-title":"P, Scheifler P L, Frances A. The Expert Consensus Guideline Series: treatment of schizophrenia 1999.","volume":"60","author":"Mc Evoy","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1176\/appi.ajp.161.1.3","article-title":"What is a mood stabilizer An evidence-base response.","volume":"161","author":"Bauer M S, Mitchner","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1399-5618.2001.030304.x","article-title":"On defining mood stabilizer..","volume":"3","year":"2001","journal-title":"Bipola Disord"},{"issue":"suppl 1","key":"R9-3-20210129","first-page":"S8","article-title":"McElroy S L, Richtand N. Tohen M What makes a drug a primary mood stabilizer.","volume":"7","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1034\/j.1399-5618.2003.02258.x","article-title":"F, Ballas C, Datto S M, et al. Ziprasidone-associated mania: a case series and review of the mechanism.","volume":"5","author":"Baldassano","year":"2003","journal-title":"Bipola Disord"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1176\/appi.ajp.159.4.673","article-title":"C. Ziprasidone induction of hypomania in depression Letter.","volume":"159","author":"Davis","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/070674370104600218","article-title":"Quetiapine-associated hypomania in a woman with schizoaffective disordeLetter.","volume":"46","author":"Benazzi","year":"2001","journal-title":"Can J Psychiatry"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0165-0327(02)00335-X","article-title":"W, Milton D F, Stauffer V L, Gelenber A, Tohen M. Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania.","volume":"73","author":"Baker","year":"2003","journal-title":"J Affect Disord"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4088\/JCP.v65n0122a","article-title":"Hypomanic episodes after receiving ziprasidone: an unintended on-off-on course of treatment Letter.","volume":"65","author":"Brieger","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.4088\/JCP.v63n1214j","article-title":"Y, Lundgren R, Escalona P R, Roberts B D. A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics.","volume":"63","author":"Lu","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R16-3-20210129","first-page":"108","article-title":"Jr, Tohen M, Banov M D, Weiss M K, Cole J O. Is clozapine a mood stabilizer.","volume":"56","year":"1995","journal-title":"J CliPsychiatry"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1176\/ajp.153.6.759","article-title":"R, Kimmel S E, Woyshville M J, et al. Clozapine for treatment-refractor mania.","volume":"153","author":"Calabrese","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4088\/JCP.v61n0502","article-title":"C, Fenzi M, Cassano G B. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study.","volume":"61","author":"Ciapparelli","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4088\/JCP.v64n0416","article-title":"Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.","volume":"64","author":"Ciapparelli","year":"2003","journal-title":"J Cli Psychiatry"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/104454602760219135","article-title":"Clozapine in adolescent inpatients with acute mania.","volume":"12","author":"Masi","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1176\/appi.ajp.157.6.982","article-title":"I, Tohen M, Patel J K, Banov M, Du Rand C, Berman I. Clozapine in the treatment of refractory psychoti mania.","volume":"157","author":"Green","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/00048679709073854","article-title":"Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standar treatment.","volume":"31","author":"Mahmood","year":"1997","journal-title":"Aust N Z J Psychiatry"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/10401239509149626","article-title":"Clozapine treatment of euphoric mania.","volume":"7","year":"1995","journal-title":"Ann Clin Psychiatry"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0006-3223(92)90108-C","article-title":"L, Gilbert J, Dessain E C, Cole J O. Clozapine in the treatment of dysphoric mania.","volume":"32","author":"Suppes","year":"1992","journal-title":"Biol Psychiatry"},{"key":"R25-3-20210129","first-page":"411","article-title":"L, Dessain E C, Pope H G Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.","volume":"52","author":"Mc Elroy","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"R26-3-20210129","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.","volume":"21","author":"Segal","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"C, Biggs J T, Ziegler V E, Meyer D A. A rating scale for mania: reliability, validity an sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","article-title":"MA, Keck P E Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.","volume":"161","author":"Hirschfeld","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"M, Mc Elroy S L, et al. Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Stud Group.","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R31-3-20210129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"G, Grundy S L, et al. Efficacy of olanzapine in acute mania: a double-blind, placebo-controlled study. Olanzapine HGGW Study Group.","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch Ge Psychiatry"},{"key":"R32-3-20210129","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4088\/JCP.v63n1210","article-title":"M, Weisler R, Sachs G, Swann A C, Wozniak P, Sommerville K W. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.","volume":"63","author":"Zajecka","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1176\/appi.ajp.159.6.1011","article-title":"W, Altshuler L L, et al. Olanzapine versus divalproex in the treatment of acut mania.","volume":"159","author":"Tohen","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R34-3-20210129","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1176\/appi.ajp.160.7.1263","article-title":"A, Zarate C A Jr, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.","volume":"160","author":"Tohen","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R36-3-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0165-0327(02)00334-8","article-title":"Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.","volume":"73","author":"Sanger T M, Tohen","year":"2003","journal-title":"J Affec Disord"},{"key":"R37-3-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004714-200304000-00005","article-title":"Acute dysphoric mania: treatment response to olanzapine versus placebo.","volume":"23","author":"Baker R W, Tohen","year":"2003","journal-title":"J Cli Psychopharmacol"},{"key":"R38-3-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1034\/j.1399-5618.2002.40103.x","article-title":"W, Goldberg J F, Tohen M, Milton D R, Stauffer V L, Schuh L M. Olanzapine vs. placebo: mania improvement is unaffected by response to previous mood stabilizer therapy.","volume":"4","author":"Baker","year":"2002","journal-title":"Bipolar Disord"},{"key":"R40-3-20210129","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archpsyc.60.12.1218","article-title":"F, Gonzalez-Pinto Arrillaga A M, et al. A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania.","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Ge Psychiatry"},{"key":"R41-3-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapinefluoxetine combination in the treatment of bipolar I depression.","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Ge Psychiatry"},{"key":"R42-3-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Jr, Versiani M, Potkin S, West S A, Giller E, Ice K. Ziprasidone in Mania Study Group Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.","volume":"160","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"suppl 4","key":"R43-3-20210129","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1016\/S0924-977X(03)92104-3","article-title":"Ziprasidone in mania: a 21-day randomized, double-blind, placebo controlled trial.","volume":"13","author":"Segal","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"R44-3-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-200102000-00007","article-title":"Jr, Reeves K R, Harrigan E P, Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies.","volume":"21","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 1","key":"R45-3-20210129","first-page":"27","article-title":"Quetiapine vs placebo for acute mania associated with bipolar disorder (STAMP 1).","volume":"5","author":"Brecher","year":"2003","journal-title":"Bipolar Disord"},{"issue":"suppl 1","key":"R46-3-20210129","first-page":"153","article-title":"Quetiapine monotherapy vs placebo for acute bipolar mania (STAMP 2).","volume":"5","author":"Paulsson","year":"2003","journal-title":"Bipolar Disord"},{"key":"R48-3-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1034\/j.1399-5618.2002.01204.x","article-title":"Quetiapine in the treatment of rapid cycling bipolar disorder.","volume":"4","author":"Vieta","year":"2002","journal-title":"Bipola Disord"},{"issue":"suppl 1","key":"R49-3-20210129","first-page":"73","article-title":"N, Goldberg J F, Henry C A, et al. Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study.","volume":"5","author":"Ghaemi","year":"2003","journal-title":"Bipolar Disord"},{"key":"R50-3-20210129","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"Jr, Marcus R, Tourkodimitris S, Aripiprazole Study Group, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.","volume":"160","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R53-3-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4088\/JCP.v61n0104","article-title":"A, Ketter T A, Leverich G S, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.","volume":"61","author":"Frye","year":"2000","journal-title":"J Cli Psychiatry"},{"issue":"suppl","key":"R54-3-20210129","first-page":"1","article-title":"Am J P","volume":"151","year":"1994","journal-title":"sychiatry"},{"key":"R55-3-20210129","first-page":"299","article-title":"Lithium and neuroleptics in combination: the spectrum of neurotoxicity.","volume":"32","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"R56-3-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4088\/JCP.v58n0503","article-title":"J, Godleski L S, Griffin R A, Mazure C M, Woods S W. Chronic neuroleptic exposure in bipolar outpatients.","volume":"58","author":"Sernyak","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"suppl","key":"R57-3-20210129","first-page":"1","article-title":"Am J P","volume":"159","year":"2002","journal-title":"sychiatry"},{"key":"R58-3-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.161.1.169","article-title":"Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted mani patients.","volume":"161","author":"Zarate C A Jr, Tohen","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R59-3-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1399-5618.2003.00034.x","article-title":"Combination treatment in bipolar disorder: a review of controlled trials.","volume":"5","year":"2003","journal-title":"Bipolar Disord"},{"key":"R60-3-20210129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to lithium or valproate monotherapy.","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch Ge Psychiatry"},{"key":"R61-3-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-5618.2004.00115.x","article-title":"Quetiapine versus placebo as adjunct to mood stabilizer for the treatment of acute bipolar mania.","volume":"6","author":"Sachs","year":"2004","journal-title":"Bipolar Disord"},{"key":"R62-3-20210129","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","article-title":"P, Schwiers M L, Rosenberg H L, Strakowski S M. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.","volume":"41","author":"Delbello","year":"2002","journal-title":"J Am Acad Child Adol Psychiatry"},{"key":"R63-3-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilizers plus risperidone or placebo in the treatment of acute mania International, double-blind, randomized controlled trial.","volume":"182","author":"Yatham L N, Grossman","year":"2003","journal-title":"Br J Psychiatry"},{"key":"R64-3-20210129","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"S, Grossman F, Ghaemi S N, Okamoto A, Bowden C L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy an safety.","volume":"159","author":"Sachs","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R66-3-20210129","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1176\/ajp.156.8.1164","article-title":"Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.","volume":"156","author":"Suppes","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R67-3-20210129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.184.4.337","article-title":"Prevention of relapse in bipolar disorder with olanzapine in combination with lithium or valproate compared to lithium or valproate monotherapy: an 18-mont study.","volume":"184","author":"Tohen","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R68-3-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10673220216279","article-title":"Optimal dosing of atypical antipsychotics in adults: a review of the current evidence.","volume":"10","author":"Citrome","year":"2002","journal-title":"Harv Rev Psychiatry"},{"key":"R69-3-20210129","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1176\/appi.ps.51.5.634","article-title":"Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.","volume":"51","author":"Citrome","year":"2000","journal-title":"Psychiat Serv"},{"key":"R70-3-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF02244953","article-title":"Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.","volume":"111","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"R71-3-20210129","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1600-0447.1991.tb03119.x","article-title":"J, Larkin E P, Shubsachs A P. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients.","volume":"84","author":"Collins","year":"1991","journal-title":"Acta Psychiatr Scand"},{"key":"R72-3-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.v65n0206","article-title":"Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized clinical trials.","volume":"65","author":"Leucht","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R73-3-20210129","first-page":"141","article-title":"Lithium-responsive schizophrenia: case reports.","volume":"46","author":"Prakash","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"R74-3-20210129","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00004714-199908000-00005","article-title":"Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathological outcome in schizophrenic patients.","volume":"19","author":"Hesslinger","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R75-3-20210129","first-page":"1","article-title":"The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.","volume":"17","author":"Simhandl","year":"1992","journal-title":"J Psychiatr Neurosci"},{"key":"R76-3-20210129","first-page":"569","article-title":"Carbamazepine in violent non-epileptic schizophrenics.","volume":"20","year":"1984","journal-title":"Psychopharmacol Bull"},{"key":"R77-3-20210129","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/070674378302800712","article-title":"Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a cas report.","volume":"28","author":"Yassa","year":"1983","journal-title":"Can J Psychiatry"},{"key":"R78-3-20210129","first-page":"1358","article-title":"Carbamazepine in treatment of violent schizophrenics Letter.","volume":"1","year":"1982","journal-title":"Lancet"},{"key":"R79-3-20210129","first-page":"326","article-title":"Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities.","volume":"44","year":"1983","journal-title":"J Clin Psychiatry"},{"key":"R80-3-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0165-1781(87)90109-0","article-title":"Carbamazepine as an adjunct of antipsychotic therapy.","volume":"22","author":"Dose","year":"1987","journal-title":"Psychiatry Res"},{"key":"R81-3-20210129","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0447.1989.tb01334.x","article-title":"A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.","volume":"80","author":"Okuma","year":"1989","journal-title":"Acta Psychiat Scand"},{"key":"R82-3-20210129","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4088\/JCP.v63n0308","article-title":"Carbamazepine augmentation for schizophrenia: how good is the evidence.","volume":"63","author":"Leucht","year":"2002","journal-title":"J Cli Psychiatry"},{"issue":"suppl 2","key":"R83-3-20210129","first-page":"74","article-title":"Schizophrenia and valproate.","volume":"37","author":"Citrome","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"R84-3-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004714-200102000-00006","article-title":"A, Hafiz N G, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications.","volume":"21","author":"Wassef","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R85-3-20210129","first-page":"509","article-title":"Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor.","volume":"14","author":"Nagao","year":"1979","journal-title":"Biol Psychiatry"},{"key":"R86-3-20210129","first-page":"1212","article-title":"Effect of valproic acid on schizophrenic syndromes in German.","volume":"30","author":"Gundurewa","year":"1980","journal-title":"Arzneimittelforschung Dru Res"},{"key":"R87-3-20210129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1192\/bjp.129.2.114","article-title":"Effect of sodium valproate on tardiv dyskinesia.","volume":"129","author":"Linnoila","year":"1976","journal-title":"Br J Psychiatry"},{"key":"R88-3-20210129","first-page":"297","article-title":"C, Basile R, Mauri M, Cazzullo C L. Le valpromide dans le traitment detats psychotiques aigus: une etude clinique ouverte in French.","volume":"86","author":"Altamura","year":"1986","journal-title":"Acta Psychiat Belg"},{"key":"R89-3-20210129","first-page":"199","article-title":"Treatment of resistant schizophrenia with valproate and neuroleptic drugs.","volume":"11","author":"Morinigo","year":"1989","journal-title":"Hillside J Cli Psychiatry"},{"key":"R90-3-20210129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004714-198902000-00010","article-title":"Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report.","volume":"9","author":"Wassef","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"R91-3-20210129","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4088\/JCP.v59n0806a","article-title":"A, Tan C H, Lee E L, Liow P H. Augmentation of risperidone with valproic acid.","volume":"59","author":"Chong","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R92-3-20210129","first-page":"16","article-title":"L, Keck P E, Pope H G. Sodium valproate: its use in primary psychiatric disorders.","volume":"7","author":"Mc Elroy","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"R93-3-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1192\/bjp.137.3.240","article-title":"Sodium valproate in schizophrenia: some biochemica correlates.","volume":"137","author":"Lautin","year":"1980","journal-title":"Br J Psychiatry"},{"key":"R94-3-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0006-3223(85)90085-X","article-title":"N, Korpi E R, Freed W J, Zalcman S J, Bigelow L B. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenia patients.","volume":"20","author":"Ko","year":"1985","journal-title":"Biol Psychiatry"},{"key":"R95-3-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-2007-979312","article-title":"Combined treatment of schizophrenic psychoses with haloperidol and valproate.","volume":"31","author":"Dose","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"R96-3-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00004714-200006000-00011","article-title":"A, Dott S G, Harris A, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia.","volume":"20","author":"Wassef","year":"2000","journal-title":"J Cli Psychopharmacol"},{"key":"R97-3-20210129","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1192\/bjp.150.4.542","article-title":"The effect of sodium valproate on tardiv dyskinesiarevisited.","volume":"150","year":"1987","journal-title":"Br J Psychiatry"},{"key":"R98-3-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0447.1977.tb00174.x","article-title":"A standardized psychiatric assessment scale for rating chronic psychotic patients.","volume":"55","author":"Krawiecka","year":"1977","journal-title":"Acta Psychiatr Scand"},{"key":"R99-3-20210129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.npp.1300023","article-title":"E, Daniel D G, Wassef A A, Tracy K A, Wozniak P, Sommerville K W. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.","volume":"28","author":"Casey","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R100-3-20210129","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ps.55.3.290","article-title":"E, Daniel D G, Wozniak P, Kochan L D, Tracy K A. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.","volume":"55","author":"Citrome","year":"2004","journal-title":"Psychiatr Serv"},{"key":"R101-3-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2004.01.016","article-title":"Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials.","volume":"70","author":"Basan","year":"2004","journal-title":"Schizophr Res"},{"key":"R102-3-20210129","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000125687.27961.64","article-title":"A study of the safety, efficacy and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.","volume":"24","author":"Citrome","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R103-3-20210129","first-page":"1241","article-title":"Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled trial. Bio.","volume":"54","author":"Tiihonen","year":"2003","journal-title":"Psychiatry"},{"key":"R104-3-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopsych.2004.06.029","article-title":"Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia.","volume":"56","author":"Kremer","year":"2004","journal-title":"Bio Psychiatry"},{"key":"R105-3-20210129","first-page":"305","article-title":"Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders.","volume":"43","author":"Chouinard","year":"1998","journal-title":"Can J Psychiatry"},{"key":"R106-3-20210129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1345\/aph.10352","article-title":"L, Devitt P J, Sauro M D, Dewan M J. Gabapentins effect on agitation in severely and persistently mentally ill patients.","volume":"35","author":"Megna","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R107-3-20210129","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1177\/070674370204701017","article-title":"Gabapentin-induced paradoxical exacerbation of psychosis in a patient wit schizophrenia.","volume":"47","author":"Jablonowski","year":"2002","journal-title":"Can J Psychiatry"},{"key":"R108-3-20210129","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00002826-200109000-00006","article-title":"L, Rosse R B, Peebles R R, Schwartz B L, Marvel C L, Deutsch S I. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.","volume":"24","author":"Drapalski","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"R109-3-20210129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.159.4.675","article-title":"C, Owen J A, Lorberg G W, Tackaberry L. Topiramate for refractory schizophrenia.","volume":"159","author":"Millson","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R110-3-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.jcp.0000085420.74359.29","article-title":"The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms.","volume":"23","author":"Baird","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R111-3-20210129","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1034\/j.1399-5618.2003.00047.x","article-title":"J, Berry J M, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients.","volume":"5","author":"Centorrino","year":"2003","journal-title":"Bipola Disord"},{"key":"R112-3-20210129","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1176\/appi.ajp.161.6.1130-a","article-title":"M, Gerth C W, Koethe D, Faulhaber J, Klosterkotter J. Oxcarbazepine as an adjunct fo schizophrenia.","volume":"161","author":"Leweke","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R114-3-20210129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/j.1950-6945.2001.tb00392.x","article-title":"Update on the mechanisms of action of antiepileptic drugs.","volume":"3","year":"2001","journal-title":"Epileptic Disord"},{"issue":"suppl 8","key":"R116-3-20210129","first-page":"5","article-title":"Mechanism of action of newer anticonvulsants.","volume":"64","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"suppl 19","key":"R117-3-20210129","first-page":"6","article-title":"Psychopharmacology of ziprasidone; receptor binding properties and real-world psychiatric practice.","volume":"64","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R118-3-20210129","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4088\/JCP.v65n0201","article-title":"Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action.","volume":"65","year":"2004","journal-title":"J Cli Psychiatry"},{"key":"R119-3-20210129","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","article-title":"S, Brown J P, Dissanayake V UK, Offord J, Thurlow R, Woodruff G N. The novel anticonvulsant drug gabapentin (Neurontin) binds to the alpha 2 delta subunit of a calcium channel.","volume":"271","author":"Gee","year":"1996","journal-title":"J Biol Chem"},{"issue":"suppl 3","key":"R121-3-20210129","first-page":"15","article-title":"The emerging differential roles of GABAergic and antiglutaminergic agents in bipolar disorders.","volume":"64","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R122-3-20210129","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1176\/appi.ajp.159.5.768","article-title":"N, Liddle P F, Shiah I S, et al. PET study of (18)F6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproe sodium.","volume":"159","author":"Yatham","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R123-3-20210129","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.jcp.0000095349.32154.a5","article-title":"GABA and schizophrenia: a review of basic science and clinical studies.","volume":"23","author":"Wassef","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R124-3-20210129","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.npp.1300461","article-title":"M, Wassef A A, Molloy M S, Williams N G. Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.","volume":"29","author":"Lopez","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"R125-3-20210129","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.npp.1300462","article-title":"Reply: valproate treatment in schizophrenia: interaction of GABA with dopamine.","volume":"29","author":"Winterer","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"R126-3-20210129","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0006-3223(00)00979-3","article-title":"K, Moore G J, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness.","volume":"48","author":"Manji","year":"2000","journal-title":"Biol Psychiatry"},{"key":"R127-3-20210129","first-page":"47","article-title":"REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mo.","volume":"2","author":"Costa","year":"2002","journal-title":"Intervent"},{"key":"R129-3-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/NMM:5:1:109","article-title":"Bipolar disorder and schizophrenia: convergent molecular data.","volume":"5","author":"Berrettini","year":"2004","journal-title":"Neuromol Med"},{"key":"R130-3-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0047.2004.00359.x","article-title":"Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia.","volume":"110","author":"Keri","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"R131-3-20210129","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","article-title":"The endophenotype concept in psychiatry: etymology and strategi intentions.","volume":"160","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R132-3-20210129","doi-asserted-by":"crossref","first-page":"982","DOI":"10.4088\/JCP.v64n0901","article-title":"Deconstructing psychiatric disorders, part 1. Genotypes, symptom phenotypes, and endophenotypes.","volume":"64","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R133-3-20210129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.v65n0102","article-title":"Symptoms and circuits, part 3: schizophrenia.","volume":"65","year":"2004","journal-title":"J Clin Psychiatry"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00023727-200501000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T06:17:41Z","timestamp":1735971461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00023727-200501000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1080\/10673220590923164","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}